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Abstract 
Background: Stearoyl‑CoA desaturase 1 (SCD1) desaturates long chain fatty acids and is therefore a key enzyme in 
fat catabolism. Its synthesis is downregulated in liver during illnesses caused by high levels of circulating lipopolysac‑
charide (LPS). SCD1 expression is known to be stimulated under adipogenic conditions through a variety of transcrip‑
tion factors, notably SREBP1 and C/EBPα and −β. However, mechanisms downregulating SCD1 expression during 
illness related reprograming of the metabolism were unknown. Escherichia coli elicited mastitis is an example of such 
a condition and was found to downregulates milk and milk fat synthesis. This is in part mediated through epigenetic 
mechanisms. We analyzed here mechanism controlling SCD1 expression in livers and udders from cows suffering 
from experimentally induced E. coli mastitis.
Results: We validated with RT‑qPCR that SCD1 expression was reduced in these organs of the experimental cows. 
They also featured decreased levels of mRNAs encoding SREBP1a but increased levels for C/EBP α and −β. Chromatin 
accessibility PCR (CHART) revealed that downregulation of SCD1 expression in liver was not caused by tighter chro‑
matin compaction of the SCD1 promoter. Reporter gene analyses showed in liver (HepG2) and mammary epithelial 
(MAC‑T) model cells that overexpression of SREBP1a expectedly activated the promoter, while unexpectedly C/EBPα 
and −β strongly quenched the promoter activity. Abrogation of two from among of the three C/EBP DNA‑binding 
motifs of the promoter revealed that C/EBPα acts in cis but C/EBPβ in trans. Overexpressing truncated C/EBPα or −β 
factors lacking their repressive domains confirmed in both model cells the direct action of C/EBPα, but not of C/EBPβ 
on the promoter.
Conclusions: We found no evidence that epigenetic mechanism remodeling the chromatin compaction of the 
SCD1 promoter would contribute to downregulate SCD1 expression during infection. Instead, our data show for the 
first time that C/EBP factors may repress SCD1 expression in liver and udder rather than stimulating as it was previ‑
ously shown in adipocytes. This cell type specific dual and opposite function of C/EBP factors for regulating SCD1 
expression was previously unknown. Infection related activation of their expression combined with downregulated 
expression of SREBP1a explains reduced SCD1 expression in liver and udder during acute mastitis.
Keywords: Cattle, C/EBP, Fat metabolism, Liver, Mastitis, SCD1, Systemic reaction, Udder
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
BMC Molecular Biology
*Correspondence:  seyfert@fbn‑dummerstorf.de 
1 Leibniz Institute for Farm Animal Biology, Institute for Genome Biology, 
Wilhelm‑Stahl‑Allee 2, 18196 Dummerstorf, Germany
Full list of author information is available at the end of the article
Page 2 of 16Xu et al. BMC Molecular Biol  (2016) 17:16 
Background
Infection of the udder causing mastitis is a frequent dis-
ease of lactating dairy cows [1]. Gram-negative patho-
gens, such as Escherichia coli (E. coli) frequently elicit 
clinical symptoms [2, 3]. These include reduced milk 
synthesis and a complete shutdown of casein synthesis, 
mediated in part through chromatin remodeling at a 
doublet STAT5-transcription factor binding site of the 
casein promoters [4]. The often generalized inflamma-
tory response during E. coli mastitis [5, 6] is conceivably 
caused through liberation and systemic circulation of 
lipopolysaccharide (LPS), that major cell envelop com-
ponent of Gram-negative bacteria. LPS binds to the Toll-
like-receptor 4 (TLR4) [7, 8]. Ligand binding triggers its 
signaling to ultimately activate the NF-κB complex of 
transcription factors. These in turn will act as a master 
switch to regulate a wealth of immune genes [9], includ-
ing pro-inflammatory cytokines such as tumor necrosis 
factor alpha (TNF-α), interleukin-1 (IL-1) and -6 (IL-6). 
All these factors are rapidly produced during udder infec-
tion—or even during sterile mastitis having experimen-
tally elicited through LPS infusion into the udder—and 
eventually initiate in the liver the expression of genes 
contributing to the acute phase response (APR) [10–13]. 
Hence, systemically circulating LPS derived from mas-
titis or other diseases such as the subacute acidosis in 
ruminants (SARA) [14] may eventually reprogram liver 
metabolism [15].
It was recently observed that the expression of the 
stearoyl-CoA desaturase 1 (SCD1) is down regulated in 
the liver of dairy cows and mammary gland of dairy goats 
during SARA, conceivably triggered through systemically 
circulating high levels of endogenous LPS derived from 
rumen [16–19]. The SCD1 enzyme is rate limiting for the 
formation of monounsaturated fatty acids by introduc-
ing a double bond on the position of Δ9. This reaction 
determines the formation of triglyceride and cholesterol 
esters in liver and mammary gland [20], hence a key pro-
cesses in fat synthesis influencing also the overall milk 
yield [21]. SCD1 plays also a role in modulating inflam-
mation and stress [22]. This may in part be conveyed 
through epigenetic mechanisms, since the SCD1 activ-
ity was found to correlate with the degree of CpG island 
DNA-methylation at the promoters of relevant immune 
genes [23]. Hormonal and nutrient factors are known to 
regulate SCD1 expression in several species including 
man and mouse [24, 25]. These multifactorial controls 
are mediated through a variety of different transcription 
factors [25]. Fine mapping and functional analyses of the 
SCD1 promoter revealed in mouse, human and cattle, 
that the sterol regulatory element-binding transcription 
factors 1 (SREBP1; see [26] for a review) and the CCAAT/
enhancer-binding protein alpha (C/EBPα) were found to 
be pivotal to cooperatively activate the expression of this 
gene in adipocytes and other cells, in particular during 
adipogenic differentiation and stimulation [27–32].
The C/EBP family of transcription factors comprises 
six members (C/EBPα, -β, -γ, -δ, -ε, -ζ). They all feature 
several domains for factor interaction and activation 
or repression of transcription [33, 34]. C/EBPα and −β 
both have a DNA binding region and a leucine zipper 
for factor dimerization. The −α factor features in addi-
tion two activation domains (AD) and one attenuator 
domain. Three activation domains and two repressive 
domains (RD) are known to mediate the function of C/
EBPβ [35, 36]. C/EBPα and −β are indispensable for adi-
pocyte differentiation and fatty acid synthesis (see [37] 
for a review). Their expression is quantitatively differen-
tiated in a tissue specific fashion and differentially regu-
lated during the acute phase response [38]. C/EBPα is 
most prominently expressed in liver and contributes to 
maintaining lipid homeostasis [34]. C/EBPβ (also known 
as NF-IL6) is the most abundant family member in the 
mammary gland. It is a key factor for regulating immune 
functions in the udder [39] but also involved in control-
ling fatty acid synthesis in the mammary epithelial cells 
(MEC) not least through regulating there the expression 
of the acetyl-CoA carboxylase-alpha (ACACA), the rate 
limiting enzyme for de novo synthesis of fatty acids ([40] 
and references therein). C/EBPα and −β are both known 
to physically bind to—and cooperatively function with—
the NF-κB p50 factor [41–44].
No information is available about mechanisms down 
regulating SCD1 expression in infected organs and tis-
sues. We wondered if epigenetic mechanisms operat-
ing during acute E. coli mastitis might be involved. We 
exploited tissues having previously been collected during 
a trial of experimentally induced clinical E. coli mastitis 
in cows [6]. It was shown in such infection experiments, 
that epigenetic mechanisms are contributing to the E. coli 
mastitis related acute shut down of casein synthesis [4] 
but also to the upregulation of infection related genes in 
the livers of the same cows during the systemic reaction 
accompanying acute mastitis [45]. Chromatin remod-
eling may modulate recruitment of transcription factors 
to their target promoters [46] and is therefore a crucial 
and diagnostic marker for the operation of such regula-
tory mechanisms. However, our analyses in the current 
study revealed no evidence for mastitis related chroma-
tin remodeling of the SCD1 promoter. Rather, we found 
that downregulated SREBP1 and—surprisingly—upregu-
lated C/EBPα and −β expression  explains the infection 
related shut down of SCD1 expression in the liver during 
E. coli mastitis. We unambiguously prove in models for 
liver and mammary epithelial cells that here the C/EBP 
factors −α and −β are repressors rather than enhancers 
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of SCD1 expression as was commonly assumed based on 
data derived from adipocytes.
Methods
Tissues, RNA extraction and chromatin preparation
Tissue samples had been collected during a trial of exper-
imental E. coli mastitis. The infection trial (including its 
ethical approval) and the analysis based on global tran-
scriptome profiling have previously been reported [6]. 
Briefly, the experimental setting involved infecting one 
udder quarter of healthy mid lactating Holstein–Frie-
sian heifers with 500 CFU of E. coli strain 1303, leaving 
3 quarters as controls. The cows were culled 24  h after 
infection. All infected quarters had developed masti-
tis with clinical signs. The trial included to sample also 
control tissues from age- and lactation stage-matched 
entirely healthy “gold standard” cows. Livers and udders 
were excised immediately after culling and within <5 min 
small cubes (0.5  cm diameter) were immediately snap 
frozen in liquid nitrogen and stored herein. Fifty mg of 
the tissue were powdered in a mortar under liquid nitro-
gen and RNA was extracted with TRIZOL (invitrogen) 
according to the manufacturer’s instructions. Chromatin 
was prepared from 100  mg of powdered liver samples, 
essentially as described [45].
Chromatin compaction assay
Chromatin compaction analysis was performed by chro-
matin accessibility by real time PCR (CHART-PCR). The 
technique involves preparation of chromatin from nuclei 
having freshly been isolated from the stored tissue and 
conducting a limited restriction digestion of the chro-
matin. Subsequently, the DNA is purified and the relative 
amount of undigested DNA from the target area is deter-
mined in quantitative PCR assays. This fraction repre-
sents the protected chromatin. We conducted the assays 
according to our previous publication [45] with some 
modifications. Briefly, 4  μl of the nuclear suspension 
were added into digestion buffer containing 40 U of the 
restriction endonuclease ScaI (for analyzing promoter 
area A; see map in Fig. 1a) or 20 U of MspI (for analysis 
of areas B and C), and incubated at 37  °C for 2  h. Sub-
sequently, DNA was purified (High Pure PCR Product 
Purification Kit; Roche) and quantified with a NanoDrop 
spectrophotometer. Seventy-five nanograms were used 
as DNA input for every measuring point of the CHART-
PCR and analysed in quantitative real-time PCR with 
the LightCycler instrument and SYBR Green I kit (both 
from Roche). Control samples were similarly treated but 
no restriction enzyme was added. These data represented 
the input control indicating 100 % protected chromatin. 
Primers are listed in the Additional file 1: Table S1.
RT‑qPCR
Primers for RT-qPCR are listed in Additional file 1: Table 
S1A. For cDNA generation, 5 μg of total RNA were tran-
scribed in reverse using SuperScript II (invitrogen) and 
the general conditions as previously described [47]. The 
cDNA was purified with the High Pure Purification kit 
(Roche) and subsequently diluted to a final effluent vol-
ume of 100  µl. For each measuring point, aliquots of 
5  µl were supplemented with amplification primers 
(20 pM) and the components of the Sybr Green I kit for 
PCR reaction. Amplification cycles consisted of an ini-
tial denaturation (95 °C, 10 min) followed by 40 cycles of 
annealing (60 °C, 30 s), elongation (72 °C, 1 min), fluores-
cence acquisition (83  °C, 5  s) and melting (95  °C, 30  s). 
Finally, the melting curves of the products were recorded. 
Quality of all PCR products was also visualized and vali-
dated in agarose gel electrophoresis. Relative copy num-
bers were calculated based on external standard curves 
obtained from dilution series (106–10 copies) of the 
cloned amplicons. Their authenticity had been verified 
by sequencing. Copy numbers were normalized relative 
to those of the “house keeping gene” SFRS4 (splicing fac-
tor, serine/arginine rich 4). Its validity as reference for 
the normalization of gene expression in liver samples has 
previously been documented [48] and we reconfirmed it 
for our samples (Additional file 1: Table S1). Primers are 
listed in the Additional file 1: Table S2A.
Reporter gene construction
Primers for cloning SCD1 promoter constructs are listed 
in Additional file 1: Table S2B. PCR was used to amplify 
the wild type (wt) promoter of SCD1 using bovine 
genomic DNA as a template. The forward and reverse 
primers introduced KpnI and HindIII restriction sites, 
respectively. We amplified a long promoter segment (PL; 
forward primer pf1, binding at –position −1767) and a 
shorter truncated promoter segment (PS; forward primer 
pf2, binding at position −884) with the common reverse 
primer pr2 (binding at position +207). PCR products 
were first cloned into pGEM-Teasy (Promega), validated 
by sequencing and the inserts were then excised via the 
artificially introduced restriction sites. They were subse-
quently cloned into the promoter-less pGL3-basic firefly 
luciferase expression vector (Promega). All clones were 
validated by sequencing.
Mutations of C/EBP binding site on the SCD1 pro-
moter constructs were generated by fusion PCR-medi-
ated mutagenesis [49] using the long reporter gene 
construct (PL) as a template. Two overlapping fragments 
were amplified for mutating the distal C/EBP binding site. 
Generation of the upstream fragment used pf1 as forward 
primer combined with the reverse primer mpr4 featuring 
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the mutated C/EBP motif. The overlapping down-
stream fragment used the mutation containing forward 
primer mpf3 and downstream the reverse primer pr2. 
Both products were purified and recovered via agarose 
gel electrophoresis. Annealing of both fragments was 
achieved by combining both fragments in a single PCR 
assay (without adding any primers) and cycling the mix-
ture 5 times using the program: Pre-denaturation (94 °C, 
5  min), followed by 5 touch-down cycles each lowering 
the annealing temperature from an initial 65 by 1 °C per 
cycle, 1 min; 72 °C, 4 min; 95 °C, 1 min. The mutated full 
length promoter fragment was recovered by next adding 
primers pf1 and pr2 and cycling another 30 times, using 
60  °C as annealing temperature. The final product was 
purified via gel electrophoresis, cloned into pGEM-Teasy 
and sequenced. Primers mpf5 and mpr6 were devised for 
the mutation of proximal C/EBP site and applying the 
same PCR strategy as described above using the short 
promoter clones as a template. The PCR products were 
cloned first into pGEM-T easy (promega) and validated 
by sequencing. Correct amplicons were cloned into the 




SREBP AP2 SP1 RBP2
+1
-884
CCGtW TTTCCCAACG                                    GGTCTGAGGAAATACGGG 





























[x105 01x[] 5] [x105]
a
b
Fig. 1 Map of SCD1 promoter in cattle and determination of SCD1 expression and chromatin compaction. a The tsp as identified in 5′‑RACE 
experiments is indicated (+1; hatched box, exon 1) and positions of selected putative transcription factor bindings sites (in silico analysis; symbols 
explained in legend below) are mapped relative to the tss. Encircled is a doubled site of overlapping C/EBP and NF‑κB binding sites, at around posi‑
tion −1020. Short kinked arrows indicate the 5′‑ends of the long and short promoter segments (PL, PS, respectively) used in reporter gene assays. 
Nucleotide sequences of two C/EBP binding sites are given below the map (core nucleotides in bold face letters). The mutated variants hereof are 
shown below (sequence alterations underlined). Gray bars label the three areas (A, B, C) having been analyzed in CHART‑PCR exploiting the restric‑
tion enzyme cutting sites as indicated by the vertical arrows. b The degree of chromatin compaction in three different promoter areas (areas A, B, 
C), as determined in CHART‑PCR (abscissa, expressed as percent of undigested control) is plotted against the levels of SCD1 mRNA concentration 
(ordinate) from healthy control cows (grey squares) or cows having experimentally been infected for 24 h with E. coli (diamonds). A Distal area A, ana‑
lyzed with primers pfA/prA and ScaI digestion; B Area around the SREBP1 binding site, analyzed with primers pfB/prB and MspI digestion. C Proximal 
area C, analyzed with primers pfC/prC and MspI digestion. The degree of chromatin compaction did not significantly differ between livers from both 
groups of cows and there was no correlation between chromatin compaction and the level of gene expression
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PL-MD and PS-MP and named long promoter with dis-
tal mutation. For muting both C/EBP sites we used clone 
PL-MD as a template, mutated the proximal site just as 
described above and designated the final clone as PL-MB 
(for both sites mutated).
Expression constructs for transcription factors
All vectors expressing transcription factors have previ-
ously been described including the validation of their 
expression with western-blots and/or via super-shifting 
with specific antibodies in EMSA analyses; those of the 
series of NFY factors from cattle (NFY-A, -B, -C) in [49]; 
those expressing the various C/EBP factors from cattle 
and their truncated DN-variants in [40]; those expressing 
the NF-κB p50 and −p65 factors from cattle in [39]. The 
vector expressing the human SREBP1a factor was a kind 
gift of Dr. J. Mao (Baylor College, Houston, TX, U.S.A.).
Cell culture, transfection and determination of the 
reporter‑gene activity
Reporter gene constructs for evaluating promoter activ-
ity were analyzed in model cells for liver using human 
hepatoma cells (HepG2; from ATCC) and mammary epi-
thelial cells (MEC) using the bovine mammary epithelia 
cell line MAC-T (kindly provided by Prof. U. Dobrindt, 
University of Münster, Germany). HepG2 cells were 
grown in MEM Earle’s medium (Biochrom, F0315) sup-
plemented with 10  % (v/v) heat-inactivated fetal calf 
serum (FCS), 1.5  g/L sodium bicarbonate, 2  mmol/L 
l-Glutamine, 0.1 mmol/L non-essential amino acids and 
1 mmol/L sodium pyruvate. MAC-T cells were cultured 
in Dulbecco’s modified Eagle’s medium (Lonza, B-4800) 
containing 5 % (v/v) heat-inactivated FCS and 4 mmol/L 
l-Glutamine.
All plasmid DNA used for transfection was prepared 
free of endotoxin using the NucleoBond Plasmid Maxi 
Xtra Purification kit (Clonetech). For transient transfec-
tions, cells were split the day before into 6-well plates and 
seeded in medium omitting antibiotics. Plasmids con-
taining the luciferase reporter gene and the respective 
expression constructs were co-transfected using Lipo-
fectamine 2000 (Life Technologies, Inc), essentially as 
previously described in detail [51]. The amount of trans-
fected DNA was kept constant, especially in dose finding 
experiments by eventually filling up to a constant amount 
with enough DNA of the empty vector of the expression 
constructs (pcDNA3.1+). The lipofectiamine and plas-
mid DNA containing transfection mixture was replaced 
after 3 h with the respective growth medium. Cells were 
lysed after 48  h with the passive lysis buffer (Promega) 
and the luciferase activity was measured using the dual 
luciferase assay reporter system (Promega). Luciferase 
activity was measured with a Berthold luminometer and 
normalized relative to the protein content of the sample. 
The latter was determined with the BioRad-protein-assay 
kit.
Rapid amplification of 5′‑cDNA ends (RACE)‑PCR
Primers for RACE-experiments are listed in Additional 
file  1: Table S1B. 5′ RACE experiments used the Gen-
eRacer™ kit (Invitrogen) essentially as prescribed. Total 
RNA extracted from healthy liver tissue served as tem-
plate to synthesizing cDNA with the specific reverse 
primer (Rpr2) and oligo dT using the Superscript II 
reverse transcriptase (invitrogen). Purified cDNA (High 
Pure PCR Purification Kit; Roche) was amplified in pri-
mary and nested PCR reactions with the primer pairs 
Rpf2/Rpr2 and Rpf1/Rpf1, respectively. The heaviest 
DNA band of the PCR products was retrieved and cloned 
into pGEM-T Easy (promega) and sequenced. The 5′ 
most located transcription start site was determined by 
comparison with the bovine genomic sequence as given 
in file AY241932.
In silico analysis of transcription factor binding sites on the 
promoter
The DNA-sequence analysis of the SCD-encoding gene 
was based on file AY241932. Potential binding sites for 
transcription factors were searched for with the MatIn-
spector program (http://www.genomatix.de/matinspec-
tor.html). Filters were set ≥0.95 for similarity of the core 
sequence and ≥0.88 for the surrounding sequence.
Statistical analysis
Significance of different mean values found between 
groups was evaluated in an unpaired T test as provided in 
the Microsoft excel program package. P < 0.05 indicated 
a significant difference.
Results
We exploited for our study as in vivo model tissue sam-
ples (udder, liver) having been collected during a well-
controlled E. coli mastitis infection trial of first lactating 
Holstein Friesian heifers. The trial included a compari-
son with age and lactation stage matched entirely healthy 
cows, serving as “gold standard” controls [6].
E. coli mastitis reduced SCD1 expression in liver and udder
We first validated with RT-qPCR measurements that 
the expression of SCD1 was indeed reduced in liver and 
infected udder quarters of our infected cows. The SCD1 
mRNA concentration in livers from the mastitis group 
(3902  ±  1909 [relative cDNA copy number,  ±  S.E.M.]) 
was only 1/3 of that found in age and lactation stage 
matched healthy cows (10,419 ± 1832; Table 1). The rela-
tive SCD1 mRNA concentration was reduced in infected 
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udder quarters; from 203,689 ± 30,739 (mean ± S.E.M.) 
cDNA copies generated from healthy glands down to 
only 1/5 of this concentration in samples generated from 
infected quarters (40,405 ± 3024). It was also reduced by 
approximately 30  % in the sterile udder quarters neigh-
boring the infected ones. We determined the concen-
tration of the ACACA-encoding mRNA as a control 
parameter for the overall rate of fatty acid synthesis. This 
was unchanged in livers from infected and healthy cows, 
but 2-fold down regulated in the infected udder quarters.
Definition of the SCD1 promoter and putative transcription 
factor binding sites
The promoter expressing the SCD1-encoding gene in 
cattle has previously not experimentally been defined. 
Rather, it was assumed that it would similarly be posi-
tioned as in the homologous genes from mouse and 
human [52]. We therefore identified the location of the 
tsp in 5′-RACE experiments using liver RNA from our 
control animals as template. We define as tsp the posi-
tion found in the most 5′-reaching isolate from among 14 
clones having been sequenced (Fig. 1a; Additional file 2: 
Figure S1). Another four clones revealed position +3 as 
5′-end, while the transcripts identified by six more clones 
initiated at position +6. Our newly defined tsp at posi-
tion +1 resides 73 upstream of the previously presumed 
location, 227 bp upstream of the start codon of transla-
tion. The latter position is widely used as a reference 
point in studies dealing with the SCD1 promoter.
The in silico analysis of the promoter sequence revealed 
attachment sites for several potentially relevant modula-
tors of transcription and transcription factors (Fig.  1a; 
Additional file  2: Figure S1). These included two factors 
known to modulate chromatin compaction (SWI/SNF; 
RBP2; [53, 54]) but also key activators of SCD1 expression 
(SREBP1, C/EBP) and other highly relevant regulators of 
fatty acid synthesis (PPAR; NF-Y; AP2, SP1). These have 
all been previously recognized in other studies. We found 
in addition previously unrecognized attachment sites for 
NF-κB, those mediators of inflammation related repro-
gramming of cellular metabolism. Intriguingly, the two 
NF-κB binding sites are closely adjacent and each site is 
almost overlapping with a C/EBP factor binding site.
Mastitis did not alter the chromatin structure of the SCD1 
promoter in liver
In searching for mechanisms downregulating SCD1 
expression in the target tissues, we examined first if 
infection would result in tightening the chromatin par-
ticularly around those putative binding sites for enhanc-
ers of SCD1 expression. Operation of such epigenetic 
mechanisms seemed plausible since we have previously 
shown in the very same liver samples that infection had 
loosened the chromatin in promoters of key immune 
genes [45]. However, measuring in the current study from 
the same samples with the same technique the degree of 
chromatin compaction in three different areas (cf Fig. 1a, 
areas A, B, C) of the SCD1 promoter did not reveal any 
infection related changes in liver samples (Table 2). Also, 
there was no correlation between the degree of chroma-
tin compaction in any of the three areas and the degree of 
SCD1 expression, as indicated by the mRNA concentra-
tion (Fig.  1b). Hence, we found no evidence that epige-
netic mechanisms acting through chromatin remodeling 
might significantly contribute to downregulate SCD1 
expression in liver during acute mastitis.
Infection differentially modulated the expression 
of SREBP1a and C/EBP factors in udder and liver
We next evaluated which of the putative transcription 
factors might be involved in the infection caused down-
regulation of SCD1 expression. We used the infection 
related changes in the mRNA abundance of the respec-
tive factors as indicator for their potential functional 
involvement. All candidate factors revealed some infec-
tion related changes in their mRNA abundance (Fig. 2a, 
Table 1 SCD1 and ACACA expression in tissues from experimental animals
Mean (± SEM) cDNA copy numbers (x103); liver: n, 6 (healthy); n, 5 (infected); MG (udder): n, 5 for each group
* P < 0.05; ** P < 0.01
Condition MG Liver
SCD1 ACACA SCD1 ACACA
Healthy 203.69 ± 3.07 11.46 ± 1.50 10.42 ± 1.83 1.83 ± 0.34
Infected 40.41 ± 3.02** 5.19 ± 0.23** 3.90 ± 1.91* 2.08 ± 0.61
Neighbor quarter 138.32 ± 19.84** 10.08 ± 1.52 – –
Table 2 Degree of chromatin compaction (%) of the SCD1 
promoter in livers
See map in Fig. 1 for area location; values are mean ± S.E.M. from n = 6 (GS, 
healthy) or n = 5 (infected) samples. For each sample the mean value from two 
separate determinations was used
Area GS Infected
A 61 ± 4 55 ± 4
B 50 ± 6 50 ± 3
C 65 ± 9 57 ± 5
Page 7 of 16Xu et al. BMC Molecular Biol  (2016) 17:16 
b; Additional file 1: Table S3A lists the respective data). 
Levels of the SREBP1a-encoding mRNA were signifi-
cantly down regulated, by 1.8-fold in liver and almost 
3-fold in the infected udder quarters. The sterile udder 
quarters neighboring the infected ones had SREBP1 
mRNA levels almost as low as the infected quarters. 
This indicates their regulation through systemic rather 
than local factors. Infection had significantly increased 
the mRNA concentrations of our other candidate fac-
tors over the levels found in the control samples. Of note, 
also concentrations of the mRNAs encoding the C/EBP 
factor series (α, β, δ) were all significantly higher in the 
liver samples from the infected animals or infected udder 
quarters.
a  Liver 
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Fig. 2 Expression of transcription factors (TF) in livers (a) or udders (b) and effect of overexpressing TFs on the promoter of SCD1 in HepG2 (c) or 
MAC‑T (d) cells. The concentration of the mRNAs encoding the respective factors was determined in RT‑qPCR and was normalized against 1000 
copies of the SFRS4 factor. a Liver samples were from healthy (GS) or udder infected cows (infected). b Udder samples were from healthy cows, 
or from sterile quarters neighboring (Neigh.) infected (Infected) ones. Error bars represent S.E.M.; asterisks indicate significance of difference to the 
value from healthy control cows (*P < 0.05; **P < 0.01). Reporter gene constructs (1 µg) expressing the Firefly‑luciferase under the control of the 
long (PL) or short (PS) promoter segment were transfected into the c HepG2 or d MAC‑T cells, together with 0.2 µg of vectors expressing the bovine 
transcription factors, as indicated. Lucifearse activity was assayed 48 h later from triplicate wells. Activity was calculated as RLU/µg of protein lysate. 
Represented are the mean values from two independent determinations and expressed as fold changes relative to controls set as 1.0 (dotted line), 
having received the reporter gene together with the empty vector used for establishing the expression constructs. Control measurements of the 
promoter‑less pGL3‑basic vector are also shown (Pgl3b). Error bars represent S.E.M.; asterisks indicate significance of difference to the value from 
healthy control cows (*P < 0.05; **P < 0.01)
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SREBP1a activated while C/EBP factors downregulated the 
activity of the SCD1 promoter
We established two reporter gene constructs to enable 
molecular analyses of the role of those candidate fac-
tors for regulating SCD1 expression. Therefore, a long 
(1767  bp; Fig.  1a) and a distally truncated (884  bp) seg-
ment of the SCD1 promoter were used to drive the 
expression of a luciferase expressing reporter gene. 
These constructs were transfected (1  µg) into HepG2 or 
MAC-T cells, serving as models for liver and mammary 
epithelial cells, respectively. For a first survey of a possi-
ble regulatory role of our candidate transcription factors, 
we co-transfected either of the two reporter gene con-
struct together with 200  ng of different vectors express-
ing either of the factors NF-κBp65; −p50; SREBP1a; C/
EBPα; −β and an equimolar mixture of vectors expressing 
the factors NFY A, -B, -C. NFY and NF-κBp65 stimulated 
the promoter activity in HepG2 cells, while NF-κB p50 
was neutral (Fig. 2c). Modulations of the promoter activ-
ity through NF-κB factors must have reflected off-target 
effects, since the short promoter does not feature a NF-κB 
binding site. These factors were all neutral or slightly 
repressive in MAC-T cells (Fig.  2d). However, we found 
as consistent effect in both model cells that SREBP1a 
strongly and significantly activated the promoter (approx-
imately 2- to 5-fold over the controls), whereas expression 
of either of the two C/EBP factors −α or −β significantly 
quenched the promoter activity, down to 50 % or less.
We scrutinized the roles of those factors exhibiting 
consistent effects in both model cells, since functional 
consistency clearly indicated their high relevance for reg-
ulating the SCD1 promoter activity. Transfecting increas-
ing amounts of these expression vectors revealed in all 
cases the dose dependence of the effect (Fig. 3). SREBP1a 
transfection similarly increased the activity of both pro-
moter segments, eventually by more than 4-fold in both 
model cells. In contrast, both C/EBP-factors quenched 
the promoter activity very clearly in a dose depend-
ent fashion. C/EBPα reduced the promoter activity of 
both promoter constructs in HepG2 cells to less than 
20 % (Fig. 3). The repressive effect was even stronger in 
MAC-T cells. Here, high amounts of transfected expres-
sion vector (1000  ng) reduced the residual activity of 
both promoters to only less than 5 % of the control.
Only in HepG2 cells appeared the effect of transfected 
C/EBPβ upon promoter activity to be similar as that of 
C/EBPα. The residual activity of the long and short pro-
moter segments was eventually lowered to only 27 or 
28  %, respectively (Fig.  3). In MAC-T cells, however C/
EBPβ quenched the activity of the short promoter seg-
ment to a larger extent than that of the long one. The 
residual activity of the long promoter segment would 
remain at ~25  % even if high amounts of the C/EBPβ 
vector were transfected but that of the short promoter 
was quenched down to almost the same low values as 
recorded from C/EBPα (< 5%).
C/EBP binding sites were repressive in HepG2, but not 
in MAC‑T cells
Given that C/EBP factors have so far been known to acti-
vate rather than repress SCD1 expression we analyzed 
in more detail the mechanism of C/EBP factor medi-
ated repression in both of our models cells. We there-
fore mutated two from among the three putative C/EBP 
binding sites (see map in Fig.  1a) in order to evaluate 
their significance for promoter activity. On the long pro-
moter construct, we mutated the distal site either alone 
or together with the proximal site. The proximal site was 
mutated on the short promoter segment. These con-
structs were transfected into both model cells (HepG2, 
MAC-T) and their activity was directly compared to 
those of the respective wt-promoter variants.
Considering first the effect of truncation of the wt-
promoter on the basal promoter activity, we found that 
deletion of the distal segment slightly, but significantly 
enhanced promoter activity in HepG2 cells (+60  %; 
Fig.  4a). The effect was in tendency similar in MAC-T 
cells (+30 %; P, 0.08).
All 3 mutations slightly enhanced the promoter activity 
in HepG2 cells, by 14, 28 and 41  % for the distal, dou-
ble or proximal mutations, respectively (Fig. 4b). In con-
trast, all three mutations lowered the promoter activity in 
MAC-T cells, down to 83, 56 and 82 % by the distal, dou-
ble or proximal mutations. The data consistently revealed 
an opposite effect of the C/EBP binding sites in both cell 
types. They slightly enhanced the promoter activity in 
HepG2 cells but lowered it in MAC-T cells.
C/EBPα, but not C/EBPβ exerted its effect in cis
The mutation analyses of the significance of the C/EBP 
binding sites had revealed only slight and even contro-
versial effects in both cell types. Hence, we wanted to 
characterize in more detail the molecular mechanism 
by which these factors repress the SCD1 promoter. We 
focused on the factors C/EBPα and C/EBPβ, given the 
well-known significance of the α-factor for adipogenesis 
and the important role of the β-factor immune functions 
and lipid synthesis in MEC. We applied two complemen-
tary approaches. On one hand, we examined the effect 
of the full length transcription factors on the reporter 
genes harboring the mutated promoters. On the other 
hand we titrated on the wt-promoters the effect of trun-
cated versions of the C/EBP factors in which the trans-
activation and repressor domains had been deleted. 
Such engineered factors are known as trans dominant 
negative (‘DN−‘) factors. Both activator domains and 
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the attenuator (repressive) domain had been deleted 
in the DN-C/EBPα factor. Both activator domains had 
also been deleted in the DN-β factor together with the 
N-terminally positioned of the two repressor domains. 
However, the second repressor domain was retained in 
DN-C/EBPβ (see schematic representation of the factor 
domains in Additional file 2: Figure S2).
Regarding the effect of the full length C/EBPα factor, 
we found that it functioned consistently in both cell lines 
in a dose dependent fashion. Increasing amounts of this 
factor were less repressive on both mutated promoters 
than on the wt-promoters (long promoter, Fig.  5; short 
promoter, Additional file  2: Figure S3). This difference 
was statistically significant (P  <  0.05) after transfecting 
200 ng or higher amounts of the factor. The effects were 
clearest at the high dose (1000  ng) of the transfected 
expression construct. This concentration lowered the 
activity of the wt-promoter in the HepG2 cells down to 
only 13 %, but the residual activity of the constructs fea-
turing the distal or doubly mutated C/EBP sites was still 
37 and 39  % respectively (Fig.  5 upper left panel). This 
difference indicated a C/EBP binding site dependent 
approximately 3-fold reduction of the repression through 
C/EBPα. The clear difference between the wt vs mutated 
C/EBP-binding site upon C/EBPα factor mediated regu-
lation of the SCD1 promoter activity validated by infer-
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Fig. 3 Response of promoter activity to increasing dose of SREBP1a or C/EBPα or −β transcription factors in HepG2 or MAC‑T cells. Reporter genes 
(1 µg) with the long or short promoter segment (PL, PS) were transfected into HepG2 or MAC‑T cells, together with increasing amounts (abscissa) 
of vectors expressing the respective transcription factor. RLUs (ordinate, untreated control set as 1) were determined 48 h after transfection, as 
described above. The total amount of transfected DNA was kept constant by eventually filling up with empty vector. Values are means calculated 
from two independent determinations, each assayed in triplicate. S.E.M. error bars of the mean values were always smaller than the size of the sym‑
bols. All, but the values for 100 ng of transfected SREBP were significantly different from the controls
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Transfection of the DN-C/EBPα factor confirmed that 
the repressor function of this factor resides in those 
domains know to directly modulate transcription. Trans-
fecting increasing amounts of the DN-C/EBPα expressing 
vector into HepG2 cells quenched the promoter activity 
to some extent. However, the effect was much weaker 
than exerted by the full-length factor and was not dose 
dependent. Even at the highest dose having been trans-
fected (1000 ng) was the activity of the reporter almost as 
high measured from the controls having not received any 
C/EBP factor expressing vector.
We obtained in MAC-T cells similar results as in 
HepG2 cells concerning the effects of the full length- or 
the DN-C/EBPα factor, using both the wt-type and the C/
EBP binding site mutated promoter variants (Fig. 5 upper 
right panel). Effects were even clearer using the short 
promoter as driver for the reporter gene (Additional 
file 2: Figure S3). The data all together show that the C/
EBPα factor indeed acts as a repressor on the SCD1 
promoter in a DNA-binding sequence motif and factor 
domain dependent fashion.
Results were different and less clear when using the C/
EBPβ factor in identical experimental settings. Consider-
ing first the effects in HepG2 cells, we observed neither 
for the long nor the short promoter any significant differ-
ence between wt-type and mutated promoters regarding 
the dose dependent repression efficacy of the full length C/
EBPβ factor (Fig. 5, lower left panel; Additional file 2: Fig-
ure S3). Transfection of 1000 ng of the expression construct 
lowered the residual activity of wt and mutated promoters 
down to 28 % for wt and the single mutated promoter; and 
31 % for the doubly mutated promoter. Hence, repression of 
SCD1 promoter activity through C/EBPβ was not depend-
ent on binding to the DNA-sequence in HepG2 cells.
Transfecting the DN-C/EBPβ factor also did not as 
clearly as DN-C/EBPα reveal a reduced repressor efficacy 
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Fig. 4 Contribution of C/EBP binding sites on the basal promoter activity. a Reporter genes harboring the long (PL) or short promoter (PS) segment 
were transfected into HepG2 or MAC‑T cells. The relative luciferase activity was determined 48 h later and was expressed as multiple of the activity 
of the promoter‑less vector pGLbasic (abscissa). Position of the distal and proximal C/EBP binding sites is indicated (C/EBPD; C/EBPP). b Activity of 
reporter genes in which either the distal C/EBP binding site (at −1020; PL‑MD) or both sites were mutated (PL‑MB). In addition, the proximal binding 
site (at −10) was mutated on the short promoter alone and the effect was recorded using the construct PS‑MP. Values are the means from two 
experiments, each assayed in triplicate. Asterisks indicate the statistical significance of the difference towards the construct with the respective wt‑
promoter
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compared to the full length factor. However, transfect-
ing high concentrations (500, 1000  ng/well) of the vec-
tor expressing this factor into HepG2 cells revealed a 
slight and statistically significant reduced repression effi-
cacy compared to the full length factor (Fig. 5 lower left 
panel). This effect was even stronger and very obvious 
when using the short promoter (Additional file 2: Figure 
S3). Hence, C/EBPβ dependent repression of the SCD1 
promoter clearly involved in HepG2 cells the N-terminal 
part of the factor comprising the activation domains and 
the repressive domain 1 (RD1).
In MAC-T cells, however we neither found any DNA-
binding sequence motif nor a factor domain dependent 
direct repressive effect of C/EBPβ. The full length factor 
was as repressive for the activity of the wt-promoters as 
for the mutated promoters (Fig.  5, lower right panel). 
Moreover, the truncated DN-C/EBPβ variant appeared to 
be an even stronger inhibitor for the activity of the long 
promoter than the full length C/EBPβ factor.
Our data together show that the molecular mecha-
nisms by which C/EBPβ represses the SCD1 activity 
are different from those of C/EBPα. Repression through 
C/EBPβ is apparently independent from the DNA-
sequence binding motif and does not involve the acti-
vator or attenuator domains. Moreover, there is a cell 
type specific modulation of the mechanisms by which 
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Fig. 5 Differentiation of the effect of C/EBPα and −β on the promoter activity. Increasing amounts of vectors (100–1000 ng) expressing C/EBPα 
(α, upper panels) or −β (β, lower panels) were transfected into HepG2 or MAC‑T cultures harboring the long segment of the wt‑promoter (black 
columns) or its variants with either the distal (striped columns) or both C/EBP binding sites mutated (checkerboard texture columns). Luciferase activity 
was recorded 48 h later and expressed as fraction of the control cultures with no C/EBP expression vector added (0 ng) set as 1. These assays were 
compared to the effect of increasing amounts of trans‑dominant negative variants (DN‑CEBP) of the respective C/EBP factors on the wt‑promoter 
(open columns). Values are means from two experiments each assayed in triplicate. Asterisks indicate statistical significance of difference (*P < 0.05; 
**P < 0.01)
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SREBP1a and C/EBPα independently exert their effect 
on the SCD1 promoter
We wondered if either the enhancer SREBP1a or the 
repressor C/EBPα would override the effect of the 
respective other factor. We therefore co-transfected 
a fixed amount (500  ng) of either the C/EBPα or the 
SREBP1 expression vector together with the reporter 
gene construct harboring the long promoter. Some of 
the C/EBPα transfections received in addition increasing 
amounts (100–1000 ng) of the SREBP1 expression vector. 
Similarly, some of the SREBP1 transfections were sup-
plemented with increasing amounts (100–1000 ng) of the 
C/EBPα expression vector. We found in both model cells 
that increasing amounts of the SREBP1 expression vector 
would significantly relief the repression through C/EBPα 



































































Fig. 6 SREBP1a and C/EBPα exert their effects independently from each other. Reporter genes (1 µg) with the long or short promoter segment 
(PL, PS) were transfected into HepG2 or MAC‑T cells together with 1000 ng of empty vector (−), 500 ng expressing C/EBPα or SREBP1a. Increasing 
amounts of vectors expressing either SREBP1a or C/EBPα (cf legend below figure) have in addition been co‑transfected in other dishes. The total 
amount of transfected DNA was kept constant in all assays by eventually filling up with empty vector. RLUs/µg of protein were determined 48 h 
after transfection and normalized against the control, set as 1. Values are means from two experiments, each assayed in triplicate. Asterisks indicate 
statistical significance of difference relative to the control having not received any expression vector for transcription factors (*P < 0.05; **P < 0.001)
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reduce the stimulatory effect exerted by the SREBP1 
expression construct. We noted as cell type specific dif-
ference that the repression through C/EBPα was stronger 
in MAC-T than in HepG2 cells, similar as noted in the 
previous experiments (cf Fig. 3).
Discussion
Key motivation for our study was to see if epigenetic 
mechanisms would play a significant role in downregu-
lating SCD1 expression in liver during metabolic disor-
ders caused through increased levels of circulating LPS. 
If true, this would have opened novel strategies for the 
veterinarian to intervene systemically against the detri-
mental metabolic effects of acute mastitis or SARA, for 
example by using small molecular inhibitors of histone 
modifiers (see [55] for a review). The samples serving as 
in  vivo model for the current study had been collected 
during a previous trial into experimentally elicited E. 
coli mastitis. Clinical analyses and global transcriptome 
profiling had proven that the udder infected cows had 
suffered from clinical mastitis which had been accom-
panied by a strong systemic reaction [6]. All the infected 
udders had been reprogramed from lactation to immune 
defence, including a shutdown of milk and milk fat syn-
thesis, similar as previously reported [4]. Livers of the 
very same cows had also revealed that chromatin remod-
eling had contributed to upregulate the expression of 
immune genes including those contributing to the acute 
phase response [45].
We made two novel key observations regarding the 
down-regulation of SCD1 expression. First, no evidence 
was found for infection related enforced chromatin 
compaction of the SCD1 promoter in the livers of the 
experimental cows. Second, we found—in contrary to the 
widespread opinion in literature—that the C/EBP factors 
−α and −β are repressors rather than activators of SCD1 
expression in liver and mammary epithelial cells.
No evidence for involvement of chromatin remodeling 
or NF‑κB factors in downregulating SCD1 expression 
during inflammation
For detecting signs of the involvement of epigenetic 
mechanisms we monitored in liver samples the degree 
of promoter compaction over an area exceeding 1000 bp 
and covered also that proximal area at around that 
SREBP1a/NFY binding site (area B, Fig.  1a; Additional 
file  2: Figure S1) which had been identified in numer-
ous studies (including cattle) as key driver element of 
SCD1 expression [29–31]. In neither of the areas did we 
detect any signs of infection related changes in chroma-
tin compaction. The technical validity of our observation 
at the SCD1 promoter is underscored by the fact that 
we have previously reported infection related chromatin 
de-compaction at the promoters of immune genes using 
the very same samples and techniques [45]. Those regu-
lated genes had included TLR2, -4, LBP, HP. The chro-
matin loosening of their promoters had been contrasted 
by revealing the unaltered chromatin compaction of the 
αS1-casein promoter. Moreover, mastitis-related hypo-
methylation of the TLR4 promoter had also been found 
in these samples. On the background of these controls it 
is clear that our current study did not yield support for 
the concept to eventually counteract LPS-related distur-
bances of fat metabolism in liver through intervening 
systemically with modulators of epigenetic mechanisms. 
Sample limitation prohibited to also examine chromatin 
from udder tissue of the same animals.
We therefore set out to look for alternative mecha-
nisms downregulating SCD1 expression and conducted 
reporter gene assays in well-established model cells for 
MEC [56, 57] and liver cells [58]. Overexpressing the 
SREBP1a factor validated the well-known crucial role of 
this factor for stimulation of SCD1 expression [30]. The 
results obtained with vectors expressing the factor series 
NFY-A, -B, -C are also in line with the respective liter-
ature in that we observed in the HepG2 model for liver 
cells a significant stimulation (cf [24]) and slight repres-
sion in the MAC-T model for MEC, similar as recently 
reported using the human breast cancer line MCF7 [59]. 
The pivotal role of the NFY factor family for the basal 
and nutritional regulated activity of the SCD1 promoter 
has recently been underscored in goat MEC model cells 
[60]. We had included into this set of experiments vec-
tors expressing the NF-κB p50 and −p65 factors not 
least because of the close vicinity of their cognate pro-
moter binding site to each other and that of C/EBP fac-
tors. Closely spaced—or even overlapping—binding sites 
for these two classes of transcription factors have been 
conserved throughout vertebrate evolution on promot-
ers of immune relevant genes ([61] and references herein) 
and their interplay may regulate expression of immune 
genes in a gene- and tissue-specific fashion [39]. How-
ever, overexpressing NF-κB p50 was almost without any 
effect for the SCD1 promoter activity and overexpres-
sion of NF-κB p65 exhibited opposite effects in MAC-T 
and HepG2 cells. Moreover, co-expressing either of the 
NF-κB factors with C/EBPα did not reveal any signs for 
factor co-operation (data not shown). Hence, modulated 
expression or activity of NF-κB factors cannot be the key 
to downregulate during inflammation the SCD1 expres-
sion commonly in udder and liver.
C/EBP‑α and −β are repressors in MEC and liver cells 
and the −α factor acts in cis
The C/EBP factors −α and −β both regulated SCD1 
promoter activity into the same direction in both model 
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cells, which was—surprisingly enough—downward! C/
EBP factors have never before been reported as negative 
regulators of SCD1 expression, to the best of our knowl-
edge. Yet, expression constructs for both of these factors 
strongly quenched the activity of the SCD1 promoter in 
a dose dependent fashion in both model cells. Proper 
expression and DNA-sequence dependent binding of 
these factors and their DN-variants has previously been 
documented [39, 40, 50]. Our data regarding the role 
of C/EBPα as a repressor for the activity SCD1 in MEC 
and liver cells are consistent in all aspects and in both of 
our model cells. This factor repressed SCD1 activity in 
a DNA-sequence motif and repressor domain depend-
ent fashion, leaving no doubt that it properly exerted this 
function acting directly in cis.
The role of C/EBPα is different in adipocytes. Christy 
et  al. [27] expressed C/EBPα in 3T3-L1 preadipocytes 
(from mouse) and convincingly proved strong activa-
tion (>20-fold) of the murine SCD1 promoter through 
this factor. Others, however only inferred a C/EBP fac-
tor dependent activation of the SCD1 promoter just from 
the observed unidirectional and co-regulated expression 
of SREBP1 and C/EBP factors in the same cells [28, 32] 
or the presence of C/EBP factor DNA-binding motifs on 
the promoter [30]. However, C/EBP factors exert multi-
ple functions and their expression is under multifacto-
rial controls [62]. Combining our data with the evidence 
from literature suggests a tissue specific differentiated 
function of C/EBPα for regulating SCD1 expression, act-
ing repressive in liver and mammary epithelial cells but 
as an enhancer in adipocytes. Recognizing tissue spe-
cific adverse functioning of transcription factors is not 
uncommon. We have previously observed, for example 
that NF-κBp65 may either enhance or strongly repress 
the activity of the CXCL8 promoter from cattle depend-
ing upon the cell-type [39].
C/EBPβ is known to sometimes acting in trans
The efficacy of C/EBPβ to repressing the activity of the 
SCD1 promoter in both of our model cells was similar as 
that of C/EBPα but apparently mediated through a dif-
ferent mechanism. Repression of the β-factor was inde-
pendent from the DNA-sequence motif. This requires 
assuming that the effect of C/EBPβ is relayed onto the 
SCD1 promoter through interaction with a different fac-
tor. C/EBP factors (both, −α and −β) are long-known to 
eventually heteromerize in particular with NF-κB p50 
[41, 43, 44]. The NF-κB p50 factor features no trans-acti-
vation domain. However, its heteromers with C/EBP fac-
tors may eventually exploit the NF-κB p50 factor binding 
to its cognate site at the promoter and use the trans-acti-
vation domain of the C/EBP factor to stimulating activity 
of the target promoter [63]. It was found in a reciprocal 
observation that the Jun-factor repressed the activity 
of the surfactant-associated protein B promoter only if 
being tethered to C/EBP-factors (either −α or −β) having 
bound to their cognate site at the promoter [64].
Clearly, our experimental settings and data do not 
allow identifying the nature of such a factor possibly 
interacting with C/EBPβ. However, the suggested inter-
action of C/EBPβ with an auxiliary factor in MEC to cor-
porately regulate the SCD1 promoter might bear clues 
for understanding the apparently cell-type specific dif-
ferentiated effect of C/EBPβ on the activity of the SCD1 
promoter. Moreover, such a multi-layered mode of action 
could also help to understand, why this factor—acting in 
cis—is a strong enhancer of ACACA expression in MEC 
[40], while repressing the SCD1 promoter in the same 
cell type.
Conclusions
Our study shows that downregulation of SCD1 expres-
sion in liver during LPS-caused metabolic disorders 
does not involve chromatin remodeling at the promoter. 
Rather, concerted down-regulating the expression of the 
enhancer SREBP1 with concomitantly enforcing expres-
sion of the repressors C/EBPα and −β readily explains 
the downregulated SCD1 expression occurring locally in 
the udder and distantly in liver during the systemic reac-
tion elicited by acute mastitis. This explanation rests on 
our solid prove that the C/EBP factors are repressors of 
SCD1 expression in liver and mammary epithelial cells 
(MEC). Comparing our respective data with literature 
suggests that C/EBPα exerts a cell type dependent func-
tion on the SCD1 promoter, acting as an enhancer in adi-
pocytes but as a repressor in hepatocytes and MEC.
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